Two gene-editing companies are making progress, with one starting commercial sales and both nearing regulatory milestones. An AI drug discovery firm is approaching crucial trial readouts in late 2025. An obesity treatment company saw stock decline due to oral formulation data, but its injectable candidate continues to show promise.

Crispr Therapeutics and Vertex Pharmaceuticals developed Casgevy, the first gene-editing treatment for sickle cell disease and beta-thalassemia, with $30 million in sales reported in Q2 2025. Intellia Therapeutics is advancing two CRISPR gene-editing programs towards key readouts. Recursion Pharmaceuticals, powered by AI, is expecting clinical trial updates in 2025.

Viking Therapeutics is developing an obesity treatment, with the injectable version showing promising results. Several healthcare innovators are approaching pivotal stages of development, with share prices reflecting caution rather than potential. The market has overlooked their progress, presenting an opportunity for investors looking for timely buys in the healthcare sector.

Read more at Yahoo Finance: 4 Healthcare Stocks to Buy Now